Trimetazidine ( DrugBank: Trimetazidine )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症2
58肥大型心筋症2
86肺動脈性肺高血圧症1

2. 筋萎縮性側索硬化症


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04788745
(ClinicalTrials.gov)
June 29, 20212/3/2021Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)Targeting Metabolic Flexibility in ALS (MetFlex); Safety and Tolerability of Trimetazidine for the Treatment of ALSAmyotrophic Lateral Sclerosis;Motor Neuron DiseaseDrug: Trimetazidine DihydrochlorideThe University of QueenslandFightMND;UMC Utrecht;King's College London;Julius Clinical, The NetherlandsRecruiting18 Years75 YearsAll36Phase 2Australia;Netherlands;United Kingdom
2EUCTR2020-005018-17-NL
(EUCTR)
14/05/202108/04/2021Safety and tolerability of Trimetazidine in amyotrophic lateral sclerosis (ALS)Targeting metabolic flexibility in ALS (MetFlex); Safety and tolerability of Trimetazidine for the treatment of ALS - MetFlex Patients suffering from amyotrophic lateral sclerosis (ALS);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Vastarel
Product Name: Trimetazidine
Product Code: 201600930
The University of QueenslandNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
36Phase 2Australia;Netherlands

58. 肥大型心筋症


臨床試験数 : 126 薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01696370
(ClinicalTrials.gov)
April 201227/9/2012Trimetazidine Therapy in Hypertrophic CardiomyopathyA Phase 2b Randomised, Double Blind, Placebo-controlled Trial of Trimetazidine Therapy in Patients With Non-obstructive Hypertrophic CardiomyopathyHypertrophic CardiomyopathyDrug: Trimetazidine;Other: Placebo capsuleUniversity College, LondonBritish Heart FoundationRecruiting18 YearsN/ABoth90Phase 2United Kingdom
2EUCTR2011-000038-12-GB
(EUCTR)
13/09/201117/08/2011Trimetazidine therapy in Hypertrophic CardiomyopathyA Phase 2b randomised, double blind, placebo-controlled trial of trimetazidine therapy in patients with non-obstructive hypertrophic cardiomyopathy. - Trimetazidine therapy in hypertrophic cardiomyopathy Hypertrophic cardiomyopathy (non-obstructive)
MedDRA version: 16.1;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Vastarel 20mg film coated tablets
Product Name: Trimetazidine Dihydrochloride 20mg
Product Code: not applicable
INN or Proposed INN: trimetazidine dihydrochloride
Other descriptive name: 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride
University College London (UCL)NULLNot RecruitingFemale: yes
Male: yes
Phase 2United Kingdom

86. 肺動脈性肺高血圧症


臨床試験数 : 1,205 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03273387
(ClinicalTrials.gov)
September 10, 20173/9/2017The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial HypertensionThe Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension Patients in National Cardiovascular Center Harapan Kita Hospital IndonesiaPrecapillary Pulmonary HypertensionDrug: Trimetazidine;Drug: Placebo oral capsuleIndonesia UniversityNULLCompleted18 Years65 YearsAll26Phase 2/Phase 3Indonesia